You are here

  • Home
  • Archive
  • Volume 9, Issue 2
  • SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study

Article metrics

Article menu

This article has a correction. Please see:

XML
Clinical/translational cancer immunotherapy
Original research
SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study

 

Online download statistics by month:

Online download statistics by month: February 2021 to February 2026

AbstractFullPdf
Feb 2021471471152
Mar 202133133181
Apr 202114614677
May 202112412451
Jun 202112712741
Jul 202110810933
Aug 2021979727
Sep 2021898935
Oct 202113513548
Nov 202111111259
Dec 2021737317
Jan 202210210632
Feb 2022505518
Mar 2022747823
Apr 2022535318
May 2022676813
Jun 202263688
Jul 202268696
Aug 2022818212
Sep 2022666710
Oct 202277779
Nov 2022495222
Dec 2022808016
Jan 2023878719
Feb 2023979729
Mar 2023585925
Apr 2023393923
May 2023383812
Jun 2023515114
Jul 202348489
Aug 202335358
Sep 2023555513
Oct 2023787819
Nov 2023616115
Dec 2023505010
Jan 202421228
Feb 2024414110
Mar 2024444465
Apr 2024434321
May 202414148
Jun 2024424211
Jul 2024656721
Aug 2024414215
Sep 2024303112
Oct 2024535323
Nov 202427289
Dec 2024293111
Jan 2025585814
Feb 20251061069
Mar 202538385
Apr 2025565612
May 2025313215
Jun 2025191910
Feb 2026110
Total409841351283